GSK Gsk Plc

TIDMGSK

RNS Number : 8665U

GlaxoSmithKline PLC

02 April 2019

GlaxoSmithKline plc

(the 'Company')

Publication of 2019 Notice of Annual General Meeting and Notice of General Meeting relating to the proposed Consumer Healthcare Joint Venture with Pfizer, Inc

The Company will today publish on its website, www.gsk.com/en-gb/investors/shareholder-information/ the following documents, which will be distributed to shareholders shortly:

   --      2019 Notice of Annual General Meeting (the '2019 AGM Notice') 
   --      2018 Annual Summary 
   --      Circular and Notice of General Meeting (the 'Circular') 

(together, the 'AGM and GM Shareholder documents')

The Company's Annual General Meeting ('AGM') will be held on Wednesday 8 May 2019 at 2.30pm at the Sofitel London Heathrow, Terminal 5, London Heathrow Airport, TW6 2GD (the 'Sofitel').

On 19 December 2018, the Company announced that it had reached an agreement with Pfizer, Inc to combine their consumer health businesses into a world-leading Joint Venture. The transaction is subject to the approval of shareholders and the Circular contains a notice convening a general meeting of the Company to be held at the Sofitel at 3.30pm on Wednesday 8 May 2019 (or as soon thereafter as the Company's AGM convened for that date has been concluded or adjourned).

The transaction is expected to close in the second half of 2019. Further details of the transaction are set out in the Circular.

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority, the AGM and GM Shareholder documents will be submitted to the UK Listing Authority and will, in due course, be available for inspection at www.morningstar.co.uk/uk/NSM.

V A Whyte

Company Secretary

2 April 2019

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 
 GSK enquiries: 
 Global Media enquiries:   Simon Steel        +44 (0) 20 8047   (London) 
                                               5502 
                           Tim Foley          +44 (0) 20 8047   (London) 
                                               5502 
 
 US Media enquiries:       Sarah Spencer      +1 215 751 3335   (Philadelphia) 
 
 Analyst/Investor          Sarah Elton-Farr   +44 (0) 20 8047   (London) 
  enquiries:                                   5194 
                           Danielle Smith     +44 (0) 20 8047   (London) 
                                               0932 
                           James Dodwell      +44 (0) 20 8047   (London) 
                                               2406 
                           Jeff McLaughlin    +1 215 751 7002   (Philadelphia) 
 
 

Cautionary statement

The release, publication or distribution of this announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe, any applicable requirements. This announcement has been prepared for the purposes of complying with the Listing Rules and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside of England and Wales.

This announcement is not intended to, and does not constitute, or form part of, any offer to sell or an invitation to purchase or subscribe for any securities or a solicitation of any vote or approval in any jurisdiction. GSK shareholders are advised to read carefully the formal documentation in relation to the transaction once it has been despatched. Any response to the proposal should be made only on the basis of the information in the formal documentation to follow.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBBGDSCXGBGCD

(END) Dow Jones Newswires

April 02, 2019 08:00 ET (12:00 GMT)

Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024